XELOX方案与FOLFOX4方案治疗晚期结直肠癌疗效比较

Abstract
Figure/Table
References
Related Citation (6)

Download: PDF (734 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To compare the efficacy and untoward reactions of capecitabine plus oxaliplatin (XELOX) regimen and oxaliplatin plus 5 - fluorouracil/leucovorin (5-FU/LV) (FOLFOX4) in the treatment of advanced colorectal cancer. Methods Totally 95 patients with metastatic and recurring colorectal cancer were enrolled into this study. Patients were randomly divided into XELOX (n=47) and FOLFOX4 (n=48) groups. Patients in XELOX group were treated with capecitabine 1 000 mg/m², p o, bid, for 14 days, and oxaliplatin 130 mg/m², ivgtt on d 1. Patients in FOLFOX4 group were treated with oxaliplatin 85 mg/m², ivgtt on d 1; LV 200 mg/m² ivgtt for 2 h followed by 5-FU 400 mg/m² (bolus) and 5-FU 600 mg/m² (22 h-coutinous in fusion), on d 1, 2. XELOX regimen was repeated every 3 weeks for one cycle; FOLFOX4 regimen was repeated every 2 weeks, and 4 weeks for one cycle. All patients received two cycles of chemotherapy or more. The toxicity was evaluated according to RECIST criteria, Karnofsky scores and NCICTC 3.O version criteria. Results All the 95 patients were available for evaluating objective response.In XELOX group, the overall response rate was 48. 9% (CR:4, PR:19), the disease control rate was 85.1%.In FOLFOX4 group, the overall response rate was 50.0% (CR:4, PR:20), the disease control rate was 89.5%; the toxicities were well tolerated.In XELOX group, the major side effects were gastrointestinal tract reactions, hematologic toxicity, stomatitis, alopecia; their incidence rates were significantly lower than those in FOLFOX4 group (P<0.05). The peripheral nerve toxicity and thrombocytopenia incidence rates were not significantly different between the two group. The incidence rate of hand-foot syndrome was higher in XELOX group than in FOLFOX4 group (P<0.05), but the severity was less (grade Ⅰ～Ⅱ). Conclusions The response rate is not markedly different between the two regimens.XELOX regimen is safer and its use is more convenient than FOLFOX4 regimen. Therefore, XELOX regimen is worth recommending as a first line therapy for the treatment of advanced colorectal cancer patients.

Key words： capecitabine oxaliplatin 5-fluorouracil leucovorin advanced colorectal cancer

Received: 03 April 2014

ZTFLH:

R735.3

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YANG Lan
	DENG Ying
	HU Hong-Lin
	PAN Hai-Xia

Cite this article:

YANG Lan,DENG Ying,HU Hong-Lin等. Comparison between capecitabine plus oxaliplatin and 5-fluorouracil/ leucovorin( 5-FU/LV) plus oxaliplatin in treatment of 95 patients with advanced colorectal cancer[J]. , 2014, 25(3): 221-223.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2014/V25/I3/221

[1]	孙燕, 石远凯.临床肿瘤内科手册[M].5版.北京:人民卫生出版社, 2008:491-526.
[1]	孙燕, 石远凯.临床肿瘤内科手册[M].5版.北京:人民卫生出版社, 2008:491-526.
[2]	Schmoll H　J, Tabernero J, Maroun J　A, et al. Capecitabine plus oxaliplatin (XELOX) versus bolus 5-fluorouracil/leucovorin (5-FU/LV) as adjuvant therapy for stage Ⅲ colon cancer: survival follow-up of study NO16968 (XELOXA)[J]. ASCO Meeting Abstracts, 2012, 30(4):388.
[2]	Schmoll H　J, Tabernero J, Maroun J　A, et al. Capecitabine plus oxaliplatin (XELOX) versus bolus 5-fluorouracil/leucovorin (5-FU/LV) as adjuvant therapy for stage Ⅲ colon cancer: survival follow-up of study NO16968 (XELOXA)[J]. ASCO Meeting Abstracts, 2012, 30(4):388.
[3]	Ducreux M, Bennouna J, Hebbar M, et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer[J]. Int J Cancer, 2011, 128:682-690.
[3]	Ducreux M, Bennouna J, Hebbar M, et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer[J]. Int J Cancer, 2011, 128:682-690.
[4]	蔡凤丹.希罗达联合奥沙利铂治疗老年晚期结直肠癌的观察及护理[J]. 实用临床医药杂志, 2010, 1672-2353.
[4]	蔡凤丹.希罗达联合奥沙利铂治疗老年晚期结直肠癌的观察及护理[J]. 实用临床医药杂志, 2010, 1672-2353.
[5]	邱萌, 毕锋.XELOX方案治疗老年晚期结直肠癌的临床研究[J].现代预防医学, 2008, 35(11):2182-2185.
[5]	邱萌, 毕锋.XELOX方案治疗老年晚期结直肠癌的临床研究[J].现代预防医学, 2008, 35(11):2182-2185.
[6]	江波, 赵金奇, 涂长玲, 等.奥沙利铂联合卡培他滨治疗晚期结肠癌的近期疗效观察[J].肿瘤基础与临床, 2008, 21(3):232-233.
[6]	江波, 赵金奇, 涂长玲, 等.奥沙利铂联合卡培他滨治疗晚期结肠癌的近期疗效观察[J].肿瘤基础与临床, 2008, 21(3):232-233.